dr. agarwal on the talapro-2 trial in mcrpc
Published 5 years ago • 253 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
1:54
dr. agarwal on developing biomarkers of response to cabozantinib/atezolizumab in mcrpc
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
1:50
dr. agarwal on pfs2 data from the titan trial in mcspc
-
1:56
talapro-2: exposure efficacy of talazoparib and enzalutamide in mcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
2:13
dr. agarwal on the cosmic-021 trial design in castration-resistant prostate cancer
-
34:39
bladder cancer and immunotherapy with dr. arjun balar
-
47:59
advances in bladder cancer immunotherapy, with dr. arjun balar
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
1:19
talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
1:06
dr. agarwal on the checkmate-214 trial for kidney cancer
-
0:53
dr. agarwal on emerging immunotherapeutic combinations in kidney cancer
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
1:37
dr. caffo discusses enzalutamide/docetaxel combination in frontline mcrpc
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
1:44
dr. agarwal on the stampede and latitude trials for prostate cancer